Philip Morganelli
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, Hepatitis B Virus Studies, Biochemical and Molecular Research
Most-Cited Works
- → Clinical targeting of HIV capsid protein with a long-acting small molecule(2020)403 cited
- → Gold-Catalyzed Cycloisomerization of 1,5-Allenynes via Dual Activation of an Ene Reaction(2008)297 cited
- → Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase(2012)42 cited
- → Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection(2013)36 cited
- → Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes(2021)30 cited
- → A Small-Molecule Inhibitor of Hepatitis C Virus Infectivity(2013)22 cited
- → Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors(2011)18 cited
- → One-Dimensional Zigzag Chains of Cs-: The Structures and Properties of Li+(Cryptand[2.1.1])Cs- and Cs+(Cryptand[2.2.2])Cs-(2006)15 cited
- → Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection(2022)13 cited
- → Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis(2025)3 cited